Drug Profile
Rabeximod - Cyxone
Alternative Names: ROB-803Latest Information Update: 29 Jun 2022
Price :
$50
*
At a glance
- Originator OxyPharma
- Developer Cyxone; University of California
- Class Acetamides; Anti-inflammatories; Disease-modifying antirheumatics; Heterocyclic compounds with 4 or more rings; Small molecules
- Mechanism of Action Cell differentiation modulators; Macrophage inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - COVID 2019 infections
Highest Development Phases
- Phase II COVID 2019 infections; Rheumatoid arthritis
Most Recent Events
- 23 Jun 2022 Cyxone submits application to the National Institute of Pharmacy and Nutrition (OGYEI) to initiate phase IIb trial in Rheumatoid arthritis
- 12 Oct 2021 Cyxone terminates a phase-II trial in COVID-2019 infections in Slovakia (PO) (EudraCT2020-004571-41)
- 10 Aug 2021 Cyxone completes a phase-II trial in COVID-2019 infections in Slovakia (PO) (EudraCT2020-004571-41)